In a retrospective study, Lucas et al. have shown that high CIP2A protein levels are elevated at diagnosis in mononuclear cells (MNCs) and CD34+ cells from patients with CML who progressed into BC compared to patients who achieved a complete cytogenetic response (CCyR) or who had not progressed (48). Here, CIP2A is linked to breast cancer.